Now that the initial surprise has worn off regarding the FDA's decision to grant accelerated approval for Genentech Inc.'s Avastin (bevacizumab) in breast cancer, the industry can begin to digest the implications of that decision. (BioWorld Financial Watch)

Now that the initial surprise has worn off regarding the FDA's decision to grant accelerated approval for Genentech Inc.'s Avastin (bevacizumab) in breast cancer, the industry can begin to digest the implications of that decision. (BioWorld Financial Watch)

Despite a negative recommendation from the Oncologic Drugs Advisory Committee, Genentech Inc.'s Avastin (bevacizumab) gained accelerated approval from the FDA for use in combination with paclitaxel chemotherapy for the first-line treatment of metastatic HER2-negative breast cancer. (BioWorld Today)